Djenontin Elie, Costa Jean-Marc, Mousavi Bita, Nguyen Lin Do Ngoc, Guillot Jacques, Delhaes Laurence, Botterel Françoise, Dannaoui Eric
Dynamyc UPEC, EnvA, USC Anses, Faculté de Médecine de Créteil, 94010 Créteil, France.
Service de Parasitologie-Mycologie, Hôpital Universitaire Mondor, AP-HP, 8 Rue du Général Sarrail, 94010 Créteil, France.
Microorganisms. 2023 Sep 28;11(10):2429. doi: 10.3390/microorganisms11102429.
(1) Background: is a cosmopolitan mold with medical, veterinary, and agronomic concerns. Its morphological similarity to other cryptic species of the section requires molecular identification techniques that are not routinely performed. For clinical isolates of section , we present the molecular identification, susceptibility to six antifungal agents, and clinical context of source patients. (2) Methods: One hundred forty fungal clinical isolates were included in the study. These isolates, recovered over a 15-year period (2001-2015), were identified based on their morphological characteristics as belonging to section . After the subculture, sequencing of a part of the β-tubulin and calmodulin genes was performed, and resistance to azole antifungals was screened on agar plates containing itraconazole and voriconazole. Minimum inhibitory concentrations were determined for 120 isolates by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution method. (3) Results: Partial β-tubulin and calmodulin sequences analysis showed that 138/140 isolates were , 1 isolate was and 1 was . Many of the isolates came from samples collected in the context of respiratory tract colonization. Among probable or proven aspergillosis, respiratory infections were the most frequent, followed by ENT infections. Antifungal susceptibility testing was available for isolates (n = 120, all ) from one hospital. The MIC range (geometric mean MIC) in mg/L was 0.5-8 (0.77), 0.5-8 (1.03), 0.125-2 (0.25), 0.03-2 (0.22), 0.25-8 (1.91), and 0.03-0.125 (0.061) for voriconazole, isavuconazole, itraconazole, posaconazole, amphotericin B, and caspofungin, respectively. Two (1.67%) isolates showed resistance to isavuconazole according to current EUCAST breakpoints with MICs at 8 mg/L for isavuconazole and voriconazole. One of these two isolates was also resistant to itraconazole with MIC at 2 mg/L. (4) Conclusions: The present characterization of a large collection of belonging to the section confirmed that is the predominant species. It is mainly implicated in respiratory and ENT infections. The emergence of resistance highlights the need to perform susceptibility tests on section isolates.
(1) 背景：[某真菌名称]是一种具有医学、兽医和农学意义的世界性霉菌。它与[该真菌所属组的其他隐秘种]在形态上相似，需要采用非常规的分子鉴定技术。对于[该真菌所属组]的临床分离株，我们展示了其分子鉴定、对六种抗真菌药物的敏感性以及来源患者的临床背景。(2) 方法：本研究纳入了140株真菌临床分离株。这些分离株是在15年期间（2001 - 2015年）收集的，根据其形态特征鉴定为属于[该真菌所属组]。继代培养后，对部分β - 微管蛋白和钙调蛋白基因进行测序，并在含有伊曲康唑和伏立康唑的琼脂平板上筛选对唑类抗真菌药物的耐药性。通过欧洲抗菌药物敏感性试验委员会（EUCAST）肉汤微量稀释法对120株分离株测定最低抑菌浓度。(3) 结果：部分β - 微管蛋白和钙调蛋白序列分析表明，140株分离株中有138株为[具体真菌名称1]，1株为[具体真菌名称2]，1株为[具体真菌名称3]。许多分离株来自呼吸道定植背景下采集的样本。在可能或确诊的曲霉病中，呼吸道感染最为常见，其次是耳鼻喉感染。对来自一家医院的分离株（n = 120，均为[具体真菌名称1]）进行了抗真菌药敏试验。伏立康唑、艾沙康唑、伊曲康唑、泊沙康唑、两性霉素B和卡泊芬净的MIC范围（几何平均MIC）以mg/L计分别为0.5 - 8（0.77）、0.5 - 8（1.03）、0.125 - 2（0.25）、0.03 - 2（0.22）、0.25 - 8（1.91）和0.03 - 0.125（0.061）。根据当前EUCAST标准，有两株（1.67%）分离株对艾沙康唑耐药，其对艾沙康唑和伏立康唑的MIC均为8 mg/L。这两株分离株中有一株对伊曲康唑也耐药，其MIC为2 mg/L。(4) 结论：对大量属于[该真菌所属组]的[某真菌名称]的当前特征描述证实[具体真菌名称1]是主要菌种。它主要与呼吸道和耳鼻喉感染有关。耐药性的出现凸显了对[该真菌所属组]分离株进行药敏试验的必要性。
